Your Position: Home > Journal List > CHINA MEDICINE > Paper

Comparative study of the efficacy and safety of rosuvastatin in paients with acute coronary syndrome combined with hyperlipidemia

( views:201, downloads:0 )
Author:
NA Run-ping(Department of Emergency,the Rescue Center of Beijing Anzhen Hospital,Capital Medical University,Beijing 100029,China)
SUN Jun-ping(Department of Emergency,the Rescue Center of Beijing Anzhen Hospital,Capital Medical University,Beijing 100029,China)
ZHU Hong-yan(Department of Emergency,the Rescue Center of Beijing Anzhen Hospital,Capital Medical University,Beijing 100029,China)
Journal Title:
CHINA MEDICINE
Issue:
Volume 06, Issue 07, 2011
DOI:
10.3760/cma.j.issn.1673-4777.2011.07.002
Key Word:
Coronary artery disease;Hyperlipidemia;Rosuvastatin;Simvastatin

Abstract: Objective To investigate the effects and the safety of rosuvastiatin in actute coronary syndrome (ACS)complicated with hyperlipidemia.Methods Ninety patients with hyperlipidernia were randomly assigned into simvastatin group (n=42) and rosuvastatin group(n=48).They were treated with simvasmtin and rosuvastatin respeetively 10 mg/d and 10 mg/d for 1 week.Lipid profile and physical laboratory investigations for adverse effects were also assessed.Serum levels of total cholesterol (TC),triglyceride (TG),low density lipoprotein cholesterol (LDL-C),high density lipoprotein cholesterol(HDL-C)and Lp(a)were measured at the end of 1 weeks of the trial period. Results Rosuvastatin treatment was more effective than simvastatin in reducing serunl levels of TC,LDL-C and Lp(a)and in raising HDL-C.The difference of liver and kidney function of 2 groups was not statistically significant.The abilities of atorvastatin treatment group in decreasing inflammatory markers in TNF-a and CRP levels were stronger than those in the simvastatin group.Conclusion Rosuvastatin has full-scale lipid-regulating effects,especially in reducing serum levels of TC,LDL-C and Lp(a) and in raising HDL-C.

  • [1]全国高胆固醇血症控制状况多中心研究协作组.高胆固醇血症临床控制状况多中心协作研究--达标率及影响因素.中华心血管病杂志,2002,30(2):109-114.
  • [2]方圻,王钟林,宁田海,等.血脂异常防治建议.中华心血管病杂志,1997,25(3):169-175.
  • [3]Antman EM,Anbe DT,Armstrong PW,et al.ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction).Circulation,2004,110(5):588-636.
  • [4]Braunwald E,Antman EM,Beasley JW,et al.ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article:a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina).J Am Coll Cardiol,2002,40(7):1366-1374.
  • [5]Miller PS,Smith DG,Jones P.Cost effectiveness of resuvastatin in treating patients to low-densitylipoprotein cholesterol goals compared with atorvastatin,pravastatin,and simvastatin (a US Analysis of the STELLAR Trial).Am J Cardiol,2005,95(11):1314-1319.
  • [6]Keating GM,Robinson DM.Rosuvastatin:a review of its effect on athemselemsis.Am J Cardiovasc Drugs,2008,8(2):127-146.
  • [7]Shaw SM,Fildes JE,Yonan N,et al.Pleiotropic effects and cholesterol-lowering therapy.Caniiology,2009,112(1):4-12.
  • [8]Sastry P,Kaski JC.Athemsclerotic plaque regression-the role of statin therapy.Drugs Today (Barc),2010,46(8):601-608.
  • [9]Goewami B,Rajappa M,Mallika V,et al.TNF-alpha/IL-10 ratio and C-reactive protein as markers of the inflammatory response in CAD-prone North Indian patients with acute myocardial infarction.Clin Chim Acta,2009,408(1-2):14-18.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn